Scope Fluidics

Scope Fluidics Operating Cash Flow

The Operating Cash Flow of Scope Fluidics (SCP.WA) as of Oct 28, 2026 is -42.29 M PLN. In the previous year, Operating Cash Flow was -25.10 M PLN — a change of 68.46% (lower).

Operating Cash Flow

-42.29 MPLN

YoY

68.46%

Last updated:

Operating Cash Flow of Scope Fluidics is 2025 -42.29 M PLN. Operating Cash Flow of Scope Fluidics was 2024 -25.10 M PLN. It decreases by 68.46% lower compared to the previous year.

The Scope Fluidics Operating Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Cash Flow
Date
Operating Cash Flow
Jan 1, 2018
-5.38 M PLN
Jan 1, 2019
-10.48 M PLN
Jan 1, 2020
-15.96 M PLN
Jan 1, 2021
-22.19 M PLN
Jan 1, 2022
-28.16 M PLN
Jan 1, 2023
-19.06 M PLN
Jan 1, 2024
-25.10 M PLN
Jan 1, 2025
-42.29 M PLN
The Scope Fluidics Operating Cash Flow history
YEAROperating Cash FlowYoY
-42.29 MPLN+68.46%
-25.10 MPLN+31.73%
-19.06 MPLN-32.32%
-28.16 MPLN+26.89%
-22.19 MPLN+39.06%
-15.96 MPLN+52.29%
-10.48 MPLN+94.80%
-5.38 MPLN+9.07%
-4.93 MPLN+27.59%
-3.87 MPLN-821.51%
535,688.00PLN—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Scope Fluidics Stock analysis

What does Scope Fluidics do? Scope Fluidics SA generates revenue through the development and sale of disposable microfluidic systems for blood sample collection and reagent storage, targeting diagnostic and med-tech applications. The company's PCR ONE system detects bacterial and viral pathogens, while the BacterOMIC system provides data on bacterial susceptibility to antibiotics and resistance mechanisms. It offers laboratory access, workshops, and administrative services, including financing, to support its projects. Key clients include doctors, medical personnel, project managers, engineers, and academics who collaborate on its diagnostic solutions. The firm monetizes its R&D focus by providing specialized diagnostic tools and infrastructure services. Its products are designed for healthcare professionals and research institutions requiring advanced pathogen detection and antibiotic resistance analysis. By delivering both hardware systems like PCR ONE and BacterOMIC, and supporting services such as lab access and financing, Scope Fluidics SA serves the healthcare sector with tailored solutions for diagnostics and med-tech innovation. Scope Fluidics SA's revenue streams are derived from the sale of microfluidic systems, project support services, and access to its facilities. The company's target segments include medical professionals, researchers, and institutions engaged in diagnostic testing and antibiotic resistance studies. Its offerings combine hardware, software-free diagnostic tools, and collaborative infrastructure to address specific healthcare challenges in pathogen detection and treatment planning. Scope Fluidics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Scope Fluidics stock

Operating Cash Flow of Scope Fluidics is -42.29 M PLN in 2025.

Operating Cash Flow of Scope Fluidics changed from -25.10 M PLN to -42.29 M PLN, representing a 68.46% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Scope Fluidics since 2006 – with annual values, charts, and detailed analysis.

Operating cash flow measures the cash generated from core business operations. It is a pure measure of a company's ability to generate cash.

Operating Cash Flow's PLN is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Operating Cash Flow's Scope Fluidics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Scope Fluidics

All Key Metrics — Scope Fluidics